Skip to Content

Using Tequila Fructans for Drug Delivery

The fruit compounds used to make tequila could also be used to save your colon.

Researchers at the University of Guadalajara, in Mexico, have discovered that fruit compounds taken from the blue-agave plant used to make tequila can be employed as an effective method of delivering drugs to the colon. This development is important for the treatment of colon diseases because physicians have been struggling to find a drug carrier that can withstand stomach acids and deliver medications to the intestine, where they are metabolized.

The blue-agave plant is an important economic product in Mexico because of its role as the base ingredient in tequila. Now researchers are using this ingredient, a fructan compound, as a method of delivering drugs to the colon.

It has been known for many years that the blue-agave plant contains a polysaccharide known as fructan, a polymer of fructose. The compound is not hydrolyzed in acidic environments, such as the upper digestive tract, and it’s therefore able to reach the intestine fully intact. Other plants, such as the chicory, the Jerusalem artichoke, and the dandelion, also contain fructan, but unlike the blue agave, they are unable to produce the large amount of fructan needed to create an effective drug carrier.

To form a drug carrier, the researchers had to chemically modify the extracted fructans to make them nonsoluble in water. They also had to design microspheres of the compound that could encapsulate the drug. To test their method, the researchers filled the microspheres with ibuprofen and exposed them to hydrochloric acid for an hour.

Their laboratory results, presented at the 233rd national meeting of the American Chemical Society, showed the drug to be undamaged. But the group plans to continue working on the design of the microspheres. Within the next year it will be testing the effectiveness of the release of the compounds under the conditions that prevail in the colon. Then the group will move on to animal trials and even further clinical trials.

Keep Reading

Most Popular

Rendering of Waterfront Toronto project
Rendering of Waterfront Toronto project

Toronto wants to kill the smart city forever

The city wants to get right what Sidewalk Labs got so wrong.

Muhammad bin Salman funds anti-aging research
Muhammad bin Salman funds anti-aging research

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging

The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.

Yann LeCun
Yann LeCun

Yann LeCun has a bold new vision for the future of AI

One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.

images created by Google Imagen
images created by Google Imagen

The dark secret behind those cute AI-generated animal images

Google Brain has revealed its own image-making AI, called Imagen. But don't expect to see anything that isn't wholesome.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.